These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21527547)

  • 41. LmjMAPK10 offers protection against Leishmania donovani infection.
    Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
    Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.
    McCall LI; Zhang WW; Ranasinghe S; Matlashewski G
    Vaccine; 2013 Feb; 31(10):1420-5. PubMed ID: 23219435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
    Goyal DK; Keshav P; Kaur S
    Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation.
    Carrión J; Folgueira C; Soto M; Fresno M; Requena JM
    Parasit Vectors; 2011 Jul; 4():150. PubMed ID: 21794145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
    Lakshmi BS; Wang R; Madhubala R
    Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
    Mazumder S; Maji M; Ali N
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.
    Dole VS; Raj VS; Ghosh A; Madhubala R; Myler PJ; Stuart KD
    Vaccine; 2000 Oct; 19(4-5):423-30. PubMed ID: 11027804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine.
    White AC; McMahon-Pratt D
    J Infect Dis; 1990 Jun; 161(6):1313-4. PubMed ID: 2345310
    [No Abstract]   [Full Text] [Related]  

  • 52. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis.
    Dias DS; Martins VT; Ribeiro PAF; Ramos FF; Lage DP; Tavares GSV; Mendonça DVC; Chávez-Fumagalli MA; Oliveira JS; Silva ES; Gomes DA; Rodrigues MA; Duarte MC; Galdino AS; Menezes-Souza D; Coelho EAF
    Parasitology; 2018 May; 145(6):740-751. PubMed ID: 29113597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis.
    He J; Huang F; Zhang J; Chen H; Chen Q; Zhang J; Li J; Zheng Z; Chen D; Chen J
    Immunology; 2019 Jan; 156(1):94-108. PubMed ID: 30285279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
    Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
    Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
    Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
    J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.